International Flavors & Fragrances Inc IFF
We take great care to ensure that the data presented and summarized in this overview for INTERNATIONAL FLAVORS & FRAGRANCES INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding IFF
View all-
Dodge & Cox San Francisco, CA31.4MShares$2.4 Billion1.66% of portfolio
-
Vanguard Group Inc Valley Forge, PA30.2MShares$2.3 Billion0.05% of portfolio
-
Freemont Capital Pte LTD Singapore, U025.4MShares$1.93 Billion82.48% of portfolio
-
Winder Investment Pte LTD25.4MShares$1.93 Billion81.82% of portfolio
-
Black Rock Inc. New York, NY21.5MShares$1.64 Billion0.05% of portfolio
-
State Street Corp Boston, MA10.5MShares$797 Million0.04% of portfolio
-
Geode Capital Management, LLC Boston, MA6.17MShares$470 Million0.04% of portfolio
-
Van Eck Associates Corp5.66MShares$432 Million0.61% of portfolio
-
Nordea Investment Management Ab Stockholm, V75.49MShares$419 Million0.5% of portfolio
-
Norges Bank Oslo, Q85.35MShares$408 Million0.06% of portfolio
Latest Institutional Activity in IFF
Top Purchases
Top Sells
About IFF
International Flavors & Fragrances Inc., together with its subsidiaries, manufactures and sells cosmetic active and natural health ingredients for use in various consumer products in Europe, Africa, the Middle East, Greater Asia, North America, and Latin America. It operates through Nourish, Scent, Health & Biosciences, and Pharma Solutions segments. The Nourish segment offers natural and plant-based specialty food ingredients, such as flavor compounds, and savory solutions and inclusions. It also provides natural food protection ingredients consist of natural antioxidants and anti-microbials as well as beverages, sweets , and dairy products. The Scent segment provides fragrance compounds, which include fine fragrances comprising perfumes and colognes, as well as consumer fragrances; fragrance ingredients comprising synthetic and natural ingredients that could be combined with other materials to create fragrance and consumer compounds; and cosmetic active ingredients consisting of active and functional ingredients, botanicals, and delivery systems to support its customers' cosmetic and personal care product lines. The Health & Biosciences segment develops and produces enzymes, food cultures, probiotics, and specialty ingredients. The Pharma Solutions segment produces and sells cellulosics and seaweed-based pharma excipients. The company sells its products primarily to manufacturers of perfumes and cosmetics, hair and other personal care products, soaps and detergents, cleaning products, dairy, meat and other processed foods, beverages, snacks and savory foods, sweet and baked goods, dietary supplements, infant and elderly nutrition, functional food, and pharmaceutical excipients and oral care products. International Flavors & Fragrances Inc. was founded in 1833 and is headquartered in New York, New York.
Insider Transactions at IFF
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Apr 04
2025
|
Deborah Borg EVP, Chief Ppl&Culture Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,545
-9.1%
|
$185,785
$73.12 P/Share
|
Apr 04
2025
|
Deborah Borg EVP, Chief Ppl&Culture Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,602
+14.12%
|
-
|
Apr 04
2025
|
Michael De Veau CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
719
-3.58%
|
$52,487
$73.12 P/Share
|
Apr 04
2025
|
Michael De Veau CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,993
+9.21%
|
-
|
Apr 04
2025
|
Angela Strzelecki President, Pharma Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
809
-3.97%
|
$59,057
$73.12 P/Share
|
Apr 04
2025
|
Angela Strzelecki President, Pharma Solutions |
BUY
Exercise of conversion of derivative security
|
Direct |
1,761
+7.97%
|
-
|
Mar 05
2025
|
Kevin O'Byrne Director |
BUY
Open market or private purchase
|
Indirect |
6,500
+50.0%
|
$520,000
$80.44 P/Share
|
Mar 04
2025
|
Deborah Borg EVP, Chief Ppl&Culture Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
123
-0.52%
|
$9,717
$79.79 P/Share
|
Mar 04
2025
|
Deborah Borg EVP, Chief Ppl&Culture Officer |
BUY
Grant, award, or other acquisition
|
Direct |
269
+1.13%
|
-
|
Mar 04
2025
|
Michael De Veau CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
42
-0.51%
|
$3,318
$79.79 P/Share
|
Mar 04
2025
|
Michael De Veau CFO |
BUY
Grant, award, or other acquisition
|
Direct |
101
+1.21%
|
-
|
Mar 04
2025
|
Simon Herriott Pres. Health & Bioscience |
SELL
Payment of exercise price or tax liability
|
Direct |
86
-0.79%
|
$6,794
$79.79 P/Share
|
Mar 04
2025
|
Simon Herriott Pres. Health & Bioscience |
BUY
Grant, award, or other acquisition
|
Direct |
237
+2.14%
|
-
|
Mar 04
2025
|
Jennifer Amy Johnson EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
77
-1.05%
|
$6,083
$79.79 P/Share
|
Mar 04
2025
|
Jennifer Amy Johnson EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
186
+2.47%
|
-
|
Mar 04
2025
|
Angela Strzelecki President, Pharma Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
34
-0.39%
|
$2,686
$79.79 P/Share
|
Mar 04
2025
|
Angela Strzelecki President, Pharma Solutions |
BUY
Grant, award, or other acquisition
|
Direct |
96
+1.1%
|
-
|
Mar 04
2025
|
De Mendonca Ana Paula Teles President, Scent |
SELL
Payment of exercise price or tax liability
|
Direct |
15
-1.58%
|
$1,185
$79.79 P/Share
|
Mar 04
2025
|
De Mendonca Ana Paula Teles President, Scent |
BUY
Grant, award, or other acquisition
|
Direct |
35
+3.55%
|
-
|
Mar 04
2025
|
J Erik Fyrwald CEO |
BUY
Open market or private purchase
|
Direct |
25,000
+46.04%
|
$2,000,000
$80.24 P/Share
|
Last 12 Months Summary
Exercise of conversion of derivative security | 82.2K shares |
---|---|
Open market or private purchase | 31.5K shares |
Grant, award, or other acquisition | 4.9K shares |
Payment of exercise price or tax liability | 29.3K shares |
---|---|
Open market or private sale | 7.59K shares |